LTI is running human clinical studies of Lysosomaltx, our drug candidate for GBA-associated parkinsonism (GBA-AP). These clinical studies will first determine safety and tolerability in normal human volunteers, followed by Parkinson’s patients with a heterozygous mutation in the GBA1 gene.